74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Bachem Holding AG
Closed
SectorHealthcare
49.56 1.64
Overview
Share price change
24h
Min
49.38
Max
49.58
Income | 36M |
|---|---|
Sales | 240M |
P/E Sector Avg | 29.588 57.333 |
Dividend yield | 1.8 |
Profit margin | 15.046 |
Employees | 2,207 |
EBITDA | 55M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +36.11% upside |
Dividend yield Sector Avg | 1.80% 2.63% |
|---|---|
Next Earnings | 24 Jul 2025 |
Market Cap | 3.5B |
|---|---|
Previous open | 47.92 |
Previous close | 49.56 |
Bachem Holding AG Chart
Past performance is not a reliable indicator of future results.
Related News
Bachem Holding AG Forecast
Price Target
By TipRanks
36.11% upside
12 Months Forecast
Average 67.4 CHF 36.11%
High 78 CHF
Low 55 CHF
Based on 5 Wall Street analysts offering 12 month price targets forBachem Holding AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.